PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This pilot randomized phase I/II trial studies the side effects and best dose of PI3K
inhibitor BKM120 when given together with cetuximab and to see how well it works in treating
patients with recurrent or metastatic head and neck cancer. PI3K inhibitor BKM120 may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal
antibodies, such as cetuximab, can block tumor growth in different ways. Some block the
ability of tumors to grow and spread. Others find tumor cells and help kill them or carry
tumor-killing substances to them. Giving PI3K inhibitor BKM120 together with cetuximab may
kill more tumor cells